ASpdb: an integrative knowledgebase of human protein isoforms from experimental and AI-predicted structures

Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene Expressed Sample Information
	Fusion Gene and Drug/Small Molecule Search from PubMed Abstracts
	Fusion Gene and Diseases from the Found PubMed Abstracts
	Fusion Gene and Diseases from Manual Curation and Other Resource
	Details of the Found Drugs/Small Molecules
	Clinical Trials of the Found Drugs/Small Molecules
	Fusion-Positive Patients' Treatment Records
	Generative AI Summary Sentence of the Relationship Between Fusion Gene and Small Molecule that Have at Least Thrree PMIDs from PubMed.

ETV6::NTRK3

Fusion Gene Summary

Fusion Gene Summary

Fusion gene name: ETV6-NTRK3
	Hgene	Tgene
Gene symbol	ETV6	NTRK3
Gene ID	2120	4916
Gene name	ETS variant transcription factor 6	neurotrophic receptor tyrosine kinase 3
Synonyms	TEL\|TEL/ABL\|THC5\|ETV6	GP145-TrkC\|TRKC\|gp145(trkC)\|NTRK3
Cytomap	12p13.2	15q25.3
Type of gene	protein-coding	protein-coding
Description	transcription factor ETV6ETS-related protein Tel1ETV6-RUNX1 fusion proteinTEL1 oncogeneets variant gene 6 (TEL oncogene)	NT-3 growth factor receptorETS related protein-neurotrophic receptor tyrosine kinase fusion proteinETV6-NTRK3 fusionneurotrophic tyrosine kinase, receptor, type 3tyrosine kinase receptor C
Modification date	20240305	20240411
UniProtAcc	.	.

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	ETV6	GO:0000122	negative regulation of transcription by RNA polymerase II	10514502
Tgene	NTRK3	GO:0001933	negative regulation of protein phosphorylation	23027130
Tgene	NTRK3	GO:0007169	cell surface receptor protein tyrosine kinase signaling pathway	23027130
Tgene	NTRK3	GO:0008284	positive regulation of cell population proliferation	23027130
Tgene	NTRK3	GO:0010628	positive regulation of gene expression	23027130
Tgene	NTRK3	GO:0030335	positive regulation of cell migration	23027130
Tgene	NTRK3	GO:0032148	activation of protein kinase B activity	23027130
Tgene	NTRK3	GO:0033138	positive regulation of peptidyl-serine phosphorylation	23027130
Tgene	NTRK3	GO:0043406	positive regulation of MAP kinase activity	23027130
Tgene	NTRK3	GO:0050927	positive regulation of positive chemotaxis	23027130
Tgene	NTRK3	GO:0090630	activation of GTPase activity	23027130

Fusion Gene Expressed Sample Information

Fusion gene information from FusionGDB2.0 (ChiTars 5.0 and ChimerDB 4.0), COSMIC, and CCLE.

* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Sample	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
ChimerDB4	AF041811	ETV6	chr12	12022903	NTRK3	chr15	88419991
ChimerDB4	TCGA-AO-A03U-01B	ETV6	chr12	12022902	NTRK3	chr15	88483983
ChimerDB4	TCGA-AO-A03U-01B	ETV6	chr12	12022903	NTRK3	chr15	88483984
ChimerDB4	TCGA-CE-A27D-01A	ETV6	chr12	12006495	NTRK3	chr15	88576276
ChiTaRS5.0	AF041811	ETV6	chr12	12022903	NTRK3	chr15	88483987
COSMIC	10	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180677	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180678	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180679	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180680	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180681	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180682	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180683	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180684	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180685	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180686	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180963	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180964	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180965	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180966	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180967	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180968	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1180969	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183363	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183364	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183366	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183367	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183368	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183369	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183370	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183371	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183372	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183373	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183374	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183375	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183376	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183426	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183427	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183428	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183429	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183430	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183431	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183432	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183433	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183434	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183435	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183436	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183437	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183443	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183444	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1183445	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1198246	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1226448	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1226449	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1226450	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1226651	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1226652	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1226653	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227070	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227809	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227810	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227811	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227812	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227813	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227817	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227818	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227819	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227821	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227822	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227823	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227824	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227825	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227826	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227827	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227828	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227829	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227830	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227831	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227832	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227834	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227835	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227859	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227860	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227861	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1227862	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301783	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301784	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301785	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301786	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301787	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301788	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301789	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301790	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301792	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1301793	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1333007	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1333008	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346453	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346454	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346455	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346456	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346457	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346458	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346459	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346461	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346463	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346464	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346465	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346466	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1346467	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1348080	ETV6	chr12	12006495	NTRK3	chr15	88483984
COSMIC	1348365	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1348366	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1348367	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1348368	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	13	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	1745113	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	2068135	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	2068136	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	2068139	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	2068140	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	2068745	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068746	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068747	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068748	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068749	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068750	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068751	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068752	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068753	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068807	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068808	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068809	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068810	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068811	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068812	ETV6	chr12	12006495	NTRK3	chr15	88576276
COSMIC	2068813	ETV6	chr12	12022903	NTRK3	chr15	88576276
COSMIC	587226	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	5	ETV6	chr12	12022903	NTRK3	chr15	88483984
COSMIC	MCH-MN-1	ETV6	chr12	12022903	NTRK3	chr15	88483984

Statistics of # Sampled Expressed This Fusion Gene Across Four Resources.

X-axis: resources, Y-axis: # samples

Fusion Gene and Drug/Small Molecule Search from PubMed Abstracts

PubMed Abstract Search With ['A-B' AND 'drug'], ['A::B' AND 'drug'].
*We used all combinations of gene synonyms of both partner genes and all combinations of ~ 14K drugs/small molecules in three categories of libraries (05-30-2024)

Statistics of the Found Drugs/Small Molecules.

PMID	Fusion Gene Name	Drug	Study Title
29237803	ETV6-TRKC	Entrectinib	Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.
21148487	ETV6-NTRK3	BMS-754807	ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
38699646	ETV6-NTRK3	Brigatinib	Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report.
34250401	ETV6-NTRK3	Cabozantinib	Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 G623R Solvent-Front Mutation.
33028644	ETV6-NTRK3	Cabozantinib	Infantile fibrosarcoma-like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib.
28497708	ETV6-NTRK3	Carboplatin	Salivary Gland Secretory Carcinoma With High-Grade Transformation, CDKN2A/B Loss, Distant Metastasis, and Lack of Sustained Response to Crizotinib.
23811600	ETV6-NTRK3	Crizotinib	Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.
33028644	ETV6-NTRK3	Cyclophosphamide	Infantile fibrosarcoma-like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib.
34030125	ETV6-NTRK3	Entrectinib	Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
29568395	ETV6-NTRK3	Entrectinib	Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
33738452	ETV6-NTRK3	Entrectinib	The experience of successful treatment of ETV6-NTRK3-positive infant glioblastoma with entrectinib.
34250401	ETV6-NTRK3	Entrectinib	Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With ETV6-NTRK3 Fusion-Positive Carcinoma Harboring the NTRK3 G623R Solvent-Front Mutation.
38699646	ETV6-NTRK3	Entrectinib	Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report.
35735423	ETV6-NTRK3	Entrectinib	TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
37188179	ETV6-NTRK3	Entrectinib	Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma.
38357305	ETV6-NTRK3	Entrectinib	From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
37338765	ETV6-NTRK3	Entrectinib	Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
36703785	ETV6-NTRK3	Entrectinib	Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
34429303	ETV6-NTRK3	Entrectinib	Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
31965543	ETV6-NTRK3	Entrectinib	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.
36743521	ETV6-NTRK3	Entrectinib	TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
34176200	ETV6-NTRK3	Entrectinib	Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
38228123	ETV6-NTRK3	Gold	Efficacy of Fine-Needle Aspiration Cytology in Diagnosing Secretory Carcinoma of Salivary Gland: A Systematic Review and Meta-Analysis.
29568395	ETV6-NTRK3	Larotrectinib	Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
32923892	ETV6-NTRK3	Larotrectinib	Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib.
37576877	ETV6-NTRK3	Larotrectinib	Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review.
33093355	ETV6-NTRK3	Larotrectinib	Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
35761904	ETV6-NTRK3	Larotrectinib	Larotrectinib as an Effective Therapy in Congenital Infantile Fibrosarcoma: Report of Two Cases.
34036219	ETV6-NTRK3	Larotrectinib	NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
36223973	ETV6-NTRK3	Larotrectinib	Metastatic triple negative breast cancer with NTRK gene fusion on tissue but not on ctDNA molecular profile.
33622165	ETV6-NTRK3	Larotrectinib	Treatment of infantile fibrosarcoma associated to an abdominal aortic aneurysm with larotrectinib: a case report.
37097530	ETV6-NTRK3	Larotrectinib	Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series.
37188179	ETV6-NTRK3	Larotrectinib	Case Report: Identification of a novel NTRK3-AJUBA fusion co-existing with ETV6-NTRK3 fusion in papillary thyroid carcinoma.
36186229	ETV6-NTRK3	Larotrectinib	A rapid and durable response to larotrectinib in a patient with NTRK fusion-positive secretory carcinoma originating from the external auditory canal.
32223937	ETV6-NTRK3	Larotrectinib	Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
38357305	ETV6-NTRK3	Larotrectinib	From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
37338765	ETV6-NTRK3	Larotrectinib	Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
32610377	ETV6-NTRK3	Larotrectinib	[Clinicopathological characteristics of NTRK-rearranged mesenchymal tumors in childhood].
29233640	ETV6-NTRK3	Larotrectinib	Rapid Response to Larotrectinib (LOXO-101) in an Adult Chemotherapy-Naive Patients With Advanced Triple-Negative Secretory Breast Cancer Expressing ETV6-NTRK3 Fusion.
37036164	ETV6-NTRK3	Larotrectinib	Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.
30220707	ETV6-NTRK3	Larotrectinib	Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
31738425	ETV6-NTRK3	Larotrectinib	Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion.
31965543	ETV6-NTRK3	Larotrectinib	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.
36743521	ETV6-NTRK3	Larotrectinib	TRK inhibitor in a patient with metastatic triple-negative breast cancer and NTRK fusions identified via cell-free DNA analysis.
34176200	ETV6-NTRK3	Larotrectinib	Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
36610231	ETV6-NTRK3	Larotrectinib	Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
38699646	ETV6-NTRK3	Lorlatinib	Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report.
29568395	ETV6-NTRK3	Merestinib	Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
23131561	ETV6-NTRK3	Midostaurin	ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412.
36378538	ETV6-NTRK3	Paclitaxel	Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report.
31965543	ETV6-NTRK3	Repotrectinib	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.
37686522	ETV6-NTRK3	Selitrectinib	The Impact of ETV6-NTRK3 Oncogenic Gene Fusions on Molecular and Signaling Pathway Alterations.
34030125	ETV6-NTRK3	Selitrectinib	Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
31965543	ETV6-NTRK3	Selitrectinib	The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.
34429303	ETV6-NTRK3	Selitrectinib	Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
30422774	ETV6-NTRK3	Somatostatin	Primary Lung Tumors in Children: Radiologic-Pathologic Correlation From the Radiologic Pathology Archives.
38420532	ETV6-NTRK3	Tyrosine	Unraveling the spectrum of inflammatory myofibroblastic tumors in the lung: A comprehensive case series highlighting endobronchial, pleural, and lung parenchymal tumors.
38699646	ETV6-NTRK3	Tyrosine	Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report.
37686522	ETV6-NTRK3	Tyrosine	The Impact of ETV6-NTRK3 Oncogenic Gene Fusions on Molecular and Signaling Pathway Alterations.
38357305	ETV6-NTRK3	Tyrosine	From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
37142453	ETV6-NTRK3	Tyrosine	Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
37036164	ETV6-NTRK3	Venetoclax	Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-NTRK3 fusion.
33028644	ETV6-NTRK3	Vincristine	Infantile fibrosarcoma-like tumor driven by novel RBPMS-MET fusion consolidated with cabozantinib.
26849118	ETV6-NTRK3	Vincristine	Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study GroupÂ experience.

Statistics of # PMIDs per found drug for this fusion gene.

X-axis: drugs, Y-axis: # PMIDs

Fusion Gene and Diseases from the Found PubMed Abstracts

Diseases Related to This Fusion Gene from the Found PMID's MeSH terms

MeSH ID	MeSH Term
D001943	Breast Neoplasms
D018572	Disease-Free Survival; Soft Tissue Neoplasms
D012983	Disease-Free Survival; Soft Tissue Neoplasms

Fusion Gene and Diseases from Manual Curation and Other Resource

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene	Tgene	Disease	Source	PMID
ETV6	NTRK3	Pediatric Glioma	PubMed	34429303
ETV6	NTRK3	Mammary Analog Secretory Carcinoma Of Salivary Gland	MyCancerGenome
ETV6	NTRK3	Fibrosarcoma	MyCancerGenome
ETV6	NTRK3	Colon Adenocarcinoma	MyCancerGenome
ETV6	NTRK3	Pancreatic Adenocarcinoma	MyCancerGenome
ETV6	NTRK3	Thyroid Gland Papillary Carcinoma	MyCancerGenome

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner	Gene	Disease ID	Disease name	# pubmeds	Source
Hgene	ETV6	C4015537	THROMBOCYTOPENIA 5	4	CTD_human;GENOMICS_ENGLAND;UNIPROT
Hgene	ETV6	C0023485	Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	3	CTD_human
Hgene	ETV6	C0040034	Thrombocytopenia	3	CTD_human;GENOMICS_ENGLAND
Hgene	ETV6	C0023480	Leukemia, Myelomonocytic, Chronic	2	ORPHANET
Hgene	ETV6	C1332965	Congenital Mesoblastic Nephroma	2	ORPHANET
Tgene	NTRK3	C0036341	Schizophrenia	3	PSYGENET
Tgene	NTRK3	C0041696	Unipolar Depression	2	PSYGENET
Tgene	NTRK3	C1269683	Major Depressive Disorder	2	PSYGENET
Tgene	NTRK3	C1332965	Congenital Mesoblastic Nephroma	2	ORPHANET

Details of the Found Drugs/Small Molecules

Details of the Found Drugs/Small Molecules from DrugBank.

DrugBank ID	Generic Name	Drug Type	Drug Group	Structure	Weight	Chemical Formula	Synonyms	SMILES
DB11986	Entrectinib	small molecule	"approved, investigational"		560.65	C31H34F2N6O2	"Entrectinib, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide"	CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1
DB12267	Brigatinib	small molecule	"approved, investigational"		584.1	C29H39ClN7O2P	Brigatinib	COC1=CC(=CC=C1NC1=NC=C(Cl)C(NC2=CC=CC=C2P(C)(C)=O)=N1)N1CCC(CC1)N1CCN(C)CC1
DB08875	Cabozantinib	small molecule	"approved, investigational"		501.514	C28H24FN3O5	Cabozantinib	COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
DB00958	Carboplatin	small molecule	approved		371.254	C6H12N2O4Pt	"Carboplatin, Carboplatine, Carboplatino, CBDCA, cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II), cis-diammine(1,1-cyclobutanedicarboxylato)platinum, cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)"	[H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
DB08865	Crizotinib	small molecule	"approved, investigational"		450.337	C21H22Cl2FN5O	"(R)-crizotinib, Crizotinib, Crizotinibum"	C[C@@H](OC1=CC(=CN=C1N)C1=CN(N=C1)C1CCNCC1)C1=C(Cl)C=CC(F)=C1Cl
DB00531	Cyclophosphamide	small molecule	"approved, investigational"		261.086	C7H15Cl2N2O2P	"(+-)-Cyclophosphamide, (±)-2-(BIS(2-CHLOROETHYL)AMINO)TETRAHYDRO-2H-1,3,2-OXAZAPHOSPHORINE 2-OXIDE MONOHYDRATE, (RS)-Cyclophosphamide, 2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide, Anhydrous cyclophosphamide, Bis(2-chloroethy	ClCCN(CCCl)P1(=O)NCCCO1
DB14723	Larotrectinib	small molecule	"approved, investigational"		428.444	C21H22F2N6O2	Larotrectinib	O[C@H]1CCN(C1)C(=O)NC1=C2N=C(C=CN2N=C1)N1CCC[C@@H]1C1=C(F)C=CC(F)=C1
DB12130	Lorlatinib	small molecule	"approved, investigational"		406.421	C21H19FN6O2	Lorlatinib	C[C@H]1OC2=C(N)N=CC(=C2)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
DB06595	Midostaurin	small molecule	"approved, investigational"		570.649	C35H30N4O4	"4'-N-benzoylstaurosporine, Midostaurin"	CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)N1C3=C(C=CC=C3)C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O)N(C)C(=O)C1=CC=CC=C1
DB01229	Paclitaxel	small molecule	"approved, vet_approved"		853.9061	C47H51NO14	"5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, ABI-007 COMPONENT PACLITAXEL, BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4	[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
DB16826	Repotrectinib	small molecule	"approved, investigational"		355.373	C18H18FN5O2	"(3R,6S,)-45-FLUORO-3,6-DIMETHYL-5-OXA-2,8-DIAZA-1(5,3)-PYRAZOLO(1,5-A)PYRIMIDINA-4(1,2)-BENZENANONAPHAN-9-ONE, (7S,13R)-11-Fluoro-7,13-Dimethyl-6,7,13,14-Tetrahydro-1,15-Ethenopyrazolo[4,3-F][1,4,8,10]Benzoxatriazacyclotridecin-4(5H)-One, 1,15-ETHENO-1H-	C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=CC(F)=CC=C4O1)C=CN3N=C2
DB09099	Somatostatin	small molecule	"approved, investigational"		1637.9	C76H104N18O19S2	"Somatostatin, Somatostatina, Somatostatine, Somatostatinum, Synthetic growth hormone release-inhibiting hormone, Synthetic somatostatin-14"	C[C@@H](O)[C@@H]1NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CO)NC1=O)C(O)=O)NC(=O)CNC(=O)[C@H](C)N)[C@@H](C)O
DB00765	Metyrosine	small molecule	approved		195.2151	C10H13NO3	"(-)-alpha-Methyl-L-tyrosine, (–)-α-methyl-L-tyrosine, (S)-alpha-Methyltyrosine, Methyltyrosine, Metirosin, Metirosina, Métirosine, Metirosine, Metirosinum, Metyrosine, α-methyl-L-p-tyrosine, α-methyl-p-tyrosine, α-methyl-para-tyrosine, α-MPT"	C[C@](N)(CC1=CC=C(O)C=C1)C(O)=O
DB11581	Venetoclax	small molecule	"approved, investigational"		868.45	C45H50ClN7O7S	"4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]	CC1(C)CCC(CN2CCN(CC2)C2=CC=C(C(=O)NS(=O)(=O)C3=CC=C(NCC4CCOCC4)C(=C3)[N+]([O-])=O)C(OC3=CN=C4NC=CC4=C3)=C2)=C(C1)C1=CC=C(Cl)C=C1
DB00541	Vincristine	small molecule	"approved, investigational"		824.972	C46H56N4O10	"22-Oxovincaleukoblastin, 22-Oxovincaleukoblastine, Leurocristine, Vincristin, Vincristina, Vincristine, Vincristinum"	[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OC

ADME (absorption, distribution, metabolism, and excretion) Properties of the Found Drugs/Small Molecules Using the Qikprop of Schrödinger.

Molecule	# stars	# amines	# amidines	# acids	# amides	# rotors	# rtvFG	CNS	mol_MW	dipole	SASA	FOSA	FISA	PISA	WPSA	volume	donorHB	accptHB	dip^2/V	ACxDN^.5/SA	glob	QPpolrz	QPlogPC16	QPlogPoct	QPlogPw	QPlogPo/w	QPlogS	CIQPlogS	QPlogHERG	QPPCaco	QPlogBB	QPPMDCK	QPlogKp	IP(eV)	EA(eV)	# metab	QPlogKhsa	Human Oral Absorption	Percent Human Oral Absorption	SAfluorine	SAamideO	PSA	# NandO	Rule Of Five	# ringatoms	# in 34	# in 56	# noncon	# nonHatm	Rule Of Three	Jm	Spermine
Entrectinib	1	1	0	0	0	6	0	1	560.645	4.959	918.941	435.368	108.96	280.83	93.783	1702.611	2	8.2	0.0144407	0.0126195	0.7503916	60.814	16.99	28.185	14.298	5.775	-8.008	-7.618	-7.636	228.841	-0.46	362.83	-4.025	8.177	0.525	5	1.29	1	77.074	93.783	0	93.206	8	2	33	0	33	9	41	1	0
BMS-754807	1	0	0	0	0	4	1	-1	461.501	12.288	781.919	327.153	101.372	304.804	48.59	1411.327	3	7.5	0.1069807	0.0166135	0.7781954	50.67	14.703	26.874	15.28	4.528	-7.124	-6.512	-6.575	1082.901	-0.674	995.208	-1.93	8.315	0.755	1	0.705	1	100	48.59	0	103.237	10	0	28	3	25	7	34	1	0
Brigatinib	3	2	0	0	0	6	0	1	584.1	5.238	961.607	565.227	67.713	277.28	51.387	1788.438	1	12.75	0.0153438	0.0132591	0.7409974	64.215	18.313	29.943	17.098	4.04	-5.496	-5.012	-8.498	140.467	0.303	138.751	-5.34	7.779	0.313	5	0.535	3	76.079	0	0	80.704	9	1	30	0	30	9	40	0	0
Cabozantinib	1	0	0	0	0	8	1	-1	501.513	2.408	848.446	298.718	83.964	418.954	46.81	1520.565	0	6	0.0038122	0	0.7537218	53.563	15.914	21.162	9.344	6.381	-8.055	-8.065	-7.515	1583.695	-0.789	1467.559	-0.823	8.862	1.087	3	1.088	1	95.661	46.81	0	98.602	8	2	25	3	22	3	37	1	0.001
Crizotinib	1	1	0	0	0	4	0	0	450.342	1.836	705.819	276.242	115.308	196.547	117.722	1279.647	3	5.25	0.002635	0.0128833	0.8076044	44.366	13.291	22.352	12.263	4.113	-5.569	-6.085	-6.309	199.22	-0.169	422.446	-4.631	7.898	0.573	5	0.763	3	92.18	40.557	0	73.496	6	0	23	0	23	5	30	0	0
Cyclophosphamide	0	0	0	0	0	3	1	0	261.087	5.135	426.973	218.784	62.254	0	145.935	736.587	1	8.5	0.0357987	0.0199076	0.9238054	21.398	7.074	13.416	10.396	0.67	-1.594	-1.368	-2.765	2544.163	0.254	8553.179	-2.379	9.604	0.112	1	-0.966	3	91.823	0	0	41.431	4	0	6	0	6	4	14	0	27.806
Larotrectinib	1	0	0	0	1	2	0	0	428.441	3.951	704.941	296.811	106.313	221.222	80.595	1265.401	2	6.2	0.0123374	0.0124381	0.8025972	45.316	12.248	21.728	13.356	3.688	-6.308	-5.725	-4.407	742.268	-0.46	1326.136	-2.508	7.694	0.647	4	0.396	1	100	80.595	14.72	88.035	8	0	25	0	25	8	31	1	0.001
Lorlatinib	0	0	0	0	0	2	0	-2	406.418	3.336	628.512	252.012	177.909	151.734	46.857	1166.832	2	7.75	0.0095375	0.0174383	0.8528193	40.707	11.548	21.155	13.612	2.432	-5.888	-6.248	-4.637	203.607	-1.073	159.926	-4.072	8.301	0.708	4	0.234	3	82.509	46.857	0	110.044	8	0	22	0	17	2	30	1	0
Merestinib	3	0	0	0	0	4	0	-2	552.539	11.944	888.183	152.232	174.417	475.161	86.373	1608.918	1	7.5	0.088661	0.0084442	0.7476273	60.204	17.805	27.778	14.275	5.893	-9.289	-9.373	-7.882	219.735	-1.546	285.872	-2.676	8.519	1.051	1	1.294	1	77.447	86.373	0	115.66	9	2	32	0	32	0	41	1	0
Midostaurin	1	0	0	0	0	3	0	-1	570.646	4.282	702.83	258.64	76.95	367.239	0	1469.779	1	7.95	0.0124732	0.0113114	0.8895069	54.247	15.057	24.457	13.066	5.112	-5.614	-9.349	-5.071	1845.775	-0.266	959.529	-1.356	7.849	0.594	3	0.937	3	89.417	0	0	74.994	8	2	35	0	35	6	43	0	0.061
Paclitaxel	9	0	0	0	0	13	4	-2	853.918	3.085	1106.647	390.621	215.373	500.653	0	2349.483	3	17.65	0.0040507	0.0276246	0.7723323	84.306	25.334	43.472	26.164	5.449	-7.387	-10.117	-7.604	89.85	-2.627	36.579	-2.477	9.611	0.808	8	0.809	1	54.939	0	0	236.456	15	3	35	4	28	13	62	2	0
Repotrectinib	0	0	0	0	0	0	0	0	355.371	7.289	571.081	195.726	98.726	229.813	46.815	1034.405	2	5.75	0.0513649	0.0142392	0.8661532	37.438	10.349	19.304	11.938	3.04	-4.853	-4.807	-4.794	1147.304	-0.199	1035.881	-2.529	8.611	0.994	2	0.331	3	100	46.815	0	78.99	7	0	22	0	15	3	26	0	0.015
Selitrectinib	1	0	0	0	0	0	0	0	380.424	12.968	606.671	281.234	80.081	198.097	47.259	1116.16	1	6	0.1506679	0.00989	0.8577542	40.407	10.5	20.243	10.463	3.652	-5.365	-5.295	-4.778	1723.812	-0.046	1617.533	-2.298	8.656	1.156	4	0.497	3	100	47.259	0	69.099	7	0	25	0	20	7	28	0	0.008
Tyrosine	0	1	0	1	0	5	0	-1	181.191	3.643	392.324	48.949	197.573	145.802	0	627.352	4	3.75	0.0211499	0.0191168	0.9033592	17.135	7.418	13.573	11.448	-1.872	-0.624	-0.684	-2.71	8.372	-0.953	3.958	-6.23	8.873	-0.359	5	-0.847	2	32.502	0	0	96.476	4	0	6	0	6	0	13	1	0.025
Venetoclax	11	1	0	0	0	11	0	-2	868.446	7.734	1181.536	549.867	215.717	371.578	44.373	2422.563	3	13.2	0.0246915	0.0193503	0.7383035	87.282	25.958	42.26	21.542	7.215	-9.608	-12.228	-8.265	22.241	-2.23	15.66	-5.193	8.516	1.081	9	1.938	1	54.425	0	0	175.599	14	3	45	0	45	13	61	3	0
Vincristine	6	2	0	0	0	8	1	-2	824.969	6.485	1046.149	646.754	197.772	201.624	0	2246.809	2	14.25	0.0187184	0.0192635	0.7930164	80.552	21.753	38.743	20.154	5.082	-5.961	-8.946	-7.295	8.208	-1.218	3.37	-7.811	8.062	0.46	5	1.455	2	34.187	0	0	177.064	14	3	38	0	34	18	60	2	0

Clinical Trials of the Found Drugs/Small Molecules

Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion Gene
Other terms
in clinicaltrials.gov

Samll molecule
Intervention
in clinicaltrials.gov

NCT ID

Study Status

Phases

Disease

# Enrolment

Date

Fusion-Positive Patients' Treatment Records

Fusion-Positive Patients' Treatment Records in TCGA cohorts

Fusion Gene	Drugs
ETV6-NTRK3	Cyclophosphamide, Fluorouracil, Methotrexate

Pediatric Sarcoma Fusion-Positive Patients' Treatment Records in the Clinical Data Warehouse (CDW) in UTHealth.

Fusion Gene	ICD-10	Disease Name	Treatments
ETV6-NTRK3	C96.20	Congenital fibrosarcoma
ETV6-NTRK3	D41.0	Congenital mesoblastic nephroma

Generative AI Summary Sentence of the Relationship Between Fusion Gene and Small Molecule that Have at Least Thrree PMIDs from PubMed

Generative AI summary sentence of the relationship between fusion gene and small molecule that have at least thrree PMIDs from PubMed using the ChatGPT 4

Found PMIDs	Fusion Gene	Drugs	Once Sentence Summary
# pmid >1	ETV6-NTRK3	Cabozantinib	ETV6-NTRK3 and Cabozantinib: Cabozantinib is effective against ETV6-NTRK3 positive cancers.
# pmid >4	ETV6-NTRK3	Crizotinib	ETV6-NTRK3 and Crizotinib: Crizotinib, originally developed as an ALK inhibitor, also shows activity against cancers with ETV6-NTRK3 fusions.
# pmid >2	ETV6-NTRK3	Cyclophosphamide	ETV6-NTRK3 and Cyclophosphamide: Cyclophosphamide is used in chemotherapy regimens for cancers with ETV6-NTRK3 fusions, but it is not a targeted therapy.
# pmid >4	ETV6-NTRK3	Entrectinib	ETV6-NTRK3 and Entrectinib: Entrectinib is a potent inhibitor of TRK proteins and shows efficacy in treating cancers with ETV6-NTRK3 fusions.
# pmid >2	ETV6-NTRK3	Iodine	ETV6-NTRK3 and Iodine: There is limited scientific literature specifically discussing the relationship between ETV6-NTRK3 and iodine.
# pmid >4	ETV6-NTRK3	Larotrectinib	ETV6-NTRK3 and Larotrectinib: Larotrectinib is a selective TRK inhibitor used to treat solid tumors with NTRK gene fusions, including those with the ETV6-NTRK3 fusion, demonstrating significant efficacy across various cancer types.
# pmid >2	ETV6-NTRK3	Progesterone	ETV6-NTRK3 and Progesterone: The relationship between ETV6-NTRK3 and progesterone is not well-documented in scientific literature.
# pmid >2	ETV6-NTRK3	Repotrectinib	ETV6-NTRK3 and Repotrectinib: Repotrectinib has shown efficacy in preclinical studies for treating cancers with ETV6-NTRK3 fusions.
# pmid >2	ETV6-NTRK3	Selitrectinib	ETV6-NTRK3 and Selitrectinib: Selitrectinib is a TRK inhibitor that has demonstrated activity against cancers with ETV6-NTRK3 fusions.
# pmid >1	ETV6-NTRK3	Staurosporine	ETV6-NTRK3 and Staurosporine: Staurosporine reduces the viability of ETV6-NTRK3 positive cells by inhibiting cell growth and inducing apoptosis.
# pmid >4	ETV6-NTRK3	Tyrosine	ETV6-NTRK3 and Tyrosine: Tyrosine kinase inhibitors targeting TRK proteins are effective against cancers harboring ETV6-NTRK3 fusions.
# pmid >4	ETV6-NTRK3	Vincristine	ETV6-NTRK3 and Vincristine: Vincristine is a chemotherapy agent used in various cancer treatments, but it is not specifically targeted for ETV6-NTRK3 fusions.